Contact About

Conclusions & perspectives


The innovations in production processes for nanotechnology allowed to develop a completely new drug delivery system for nanomedicine of any hydrophilic active pharmaceutical ingredient of biological origin. This successful approach will be focused for the next phase of exploitation to enable a fast track to clinical trials within the next research phase.

Exploitation Perspectives

Industrial scale-up was prepared in compliance with the rules of Good Manufacturing Practice (GMP). The production technology has to be further developed to allow the execution of pre-clinical and clinical trials. The consortium partners plan to commercialize own active pharmaceutical ingredients (API) to be encapsulated in the novel drug delivery system which are to be tested clinically to prove the superior properties compared to non-encapsulated API. Simultaneously, the own drug formulation developments will be used as a showcase for the commercialization of the production technology, comprising both technological devices, processes, material compositions and their novel properties.

Socio-economic impact

The perspective of clinical trials in cancer therapy is of high societal relevance. Outreach activities and public engagement reached more than 25,000 cancer patients during the lifetime of the project. Young people of different age groups were given support by lab training allowing intriguing experiences with science. The uptake of model biopharmaceuticals such as cytotoxic proteins and green fluorescent protein-encoding RNA was elucidated by life imaging and presented to the general public in open days.

The research leading to these results has received funding from the People Programme (Marie Curie Actions) of the European
Union’s Seventh Framework Programme FP7 (2007–2013) under REA grant agreement no. 324275 (project acronym Decent AID)